Bhavik Patel Sells 1,855 Shares of IQVIA (NYSE:IQV) Stock

IQVIA Holdings Inc. (NYSE:IQV) insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

IQVIA Price Performance

IQV stock opened at $236.07 on Thursday. The business has a 50 day moving average price of $198.78 and a 200 day moving average price of $186.63. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market cap of $38.86 billion, a price-to-earnings ratio of 29.29, a PEG ratio of 1.94 and a beta of 1.18. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $251.36.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter last year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has initiated a stock repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in IQV. Franklin Street Advisors Inc. NC acquired a new stake in shares of IQVIA in the 4th quarter worth approximately $15,724,000. CWM LLC boosted its position in IQVIA by 23.9% during the fourth quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock worth $12,585,000 after purchasing an additional 10,762 shares in the last quarter. Calamos Advisors LLC grew its holdings in IQVIA by 268.1% in the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock valued at $42,536,000 after purchasing an additional 137,441 shares during the last quarter. Assetmark Inc. increased its position in shares of IQVIA by 33.6% in the fourth quarter. Assetmark Inc. now owns 172,625 shares of the medical research company’s stock valued at $38,911,000 after buying an additional 43,436 shares in the last quarter. Finally, KBC Group NV raised its stake in shares of IQVIA by 68.2% during the 4th quarter. KBC Group NV now owns 779,128 shares of the medical research company’s stock worth $175,624,000 after buying an additional 315,883 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

More IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: IQVIA exceeded second-quarter expectations, reporting adjusted EPS of $3.15 versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion. Revenue increased 8.7% year over year, while full-year 2026 EPS guidance was set at $12.80–$13.00. Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
• Positive Sentiment: Record bookings and a sizable backlog improve visibility into future revenue growth. Investors are now focused on how effectively IQVIA converts that backlog into sales and earnings. The Backlog Tells the Real Story: Inside IQVIA’s Blowout Q2
• Positive Sentiment: IQVIA and Medera announced a collaboration involving cardiac gene therapy and human-based drug discovery. The agreement could expand IQVIA’s role in specialized clinical development, though the financial impact is likely longer term. IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
• Positive Sentiment: The company’s previously authorized $2 billion share-repurchase program, representing up to 6.8% of shares, provides potential support for EPS and signals management’s confidence in the valuation.
• Neutral Sentiment: Analysts remain generally constructive, with a consensus “Moderate Buy” rating and an average price target of $241.88. However, commentary highlights execution risk following the recent rally, particularly the pace of backlog conversion. Five Insightful Analyst Questions From IQVIA’s Q2 Earnings Call
• Negative Sentiment: Insider selling may weigh modestly on sentiment. Bhavik Patel sold 1,855 shares for approximately $436,000, reducing his position by 57.91%, while W. Richard Staub sold 5,500 shares for about $1.28 million, cutting his holdings by 29.24%. These sales do not necessarily signal weakening fundamentals. IQVIA Insider Selling
• Negative Sentiment: IQVIA’s debt-to-equity ratio of 2.18 and current ratio of 0.71 underscore leverage and liquidity concerns. Continued earnings growth and disciplined execution are important to support the company’s valuation.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IQV. HSBC reiterated a “buy” rating and set a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. BMO Capital Markets increased their price objective on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Mizuho lifted their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, TD Cowen lifted their target price on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.